In this study, through high‐throughput screening using a functional isogenic BaF3 cell library, we found that nintedanib, a triple angiokinase inhibitor of FGFR/VEGFR/PDGFR that has been approved for the treatment of IPF and NSCLC, exhibited potent activity against a panel of primary gain‐of‐function (GOF) mutations and secondary drug resistance mutations in KIT kinase. This evidence concerns the gene KIT and non-small cell lung carcinoma.